Author

Rachel Bailen

Observed name: Rachel J. Bailen

Institution: Mayo Clinic

Observed institution: Mayo Clinic

OpenAlex ID: A5111343509

Incidence, risk factors, and outcomes of patients with monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia who develop venous thromboembolism

2024 · Amber B. Koehler, Kari G. Rabe, et al. · Journal of Thrombosis and Haemostasis · 3

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Mayo Clinic Systematic Management and Risk-Adapted Therapy for Lymphoid Malignancies (lySMART) Consensus Guidelines 2026

2026 · Sameer A. Parikh, Paul J. Hampel, et al. · Mayo Clinic Proceedings · 1

Progression of disease within 36 months (POD36) of starting first-line targeted therapy independently predicts poor overall survival in patients with chronic lymphocytic leukemia (CLL)

2025 · Paul Hampel, Kari Rabe, et al. · Blood · 1

Overall survival of patients with chronic lymphocytic leukemia treated with venetoclax-obinutuzumab compared to age- and sex-matched general population

2026 · Lauren D. Pomerantz, Kari G. Rabe, et al. · Leukemia & lymphoma/Leukemia and lymphoma

Characteristics and prognostic factors in adult hemophagocytic lymphohistiocytosis: A large single-institution analysis

2025 · Guneet Janda, Sameer Parikh, et al. · Blood

Venetoclax-obinutuzumab in frontline and R/R CLL: Outcomes compared to age- and sex-matched general population

2025 · Lauren Pomerantz, Sameer Parikh, et al. · Blood

Works count: 6

Citation count: 5

H-index: 1

I10-index: